6 jul 2017 ano - The JAMA Viewpoint article by Dr. Scott Gottlieb and Dr. Janet Woodcock entitled, “Marshaling FDA Benefit-Risk Expertise to Address the Current Opioid Abuse Epidemic," was published. Following the FDA’s request, Endo announced that it would voluntarily remove reformulated Opana ER from the market.

Adicionado na linha do tempo:

Opioids and the FDA

ByAnastasia

13 nov 2018

0 0 330

Data: